Frontotemporal Lobar Degeneration: A Clinical Approach

Elissaios Karageorgiou, MD^{1,2} Bruce L. Miller, MD¹

¹ Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, California

² Neurological Institute of Athens, Athens, Greece

Address for correspondence Bruce L. Miller, MD, Department of Neurology, Memory and Aging Center, University of California San Francisco, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158 (e-mail: bmiller@memory.ucsf.edu).

Semin Neurol 2014;34:189–201.

Abstract

In this review, the authors outline a clinical approach to frontotemporal lobar degeneration (FTLD), a term coined to describe a pathology associated with atrophy of the frontal and temporal lobes commonly seen with abnormal protein aggregates. It accounts for ~10% of pathologically confirmed dementias. The three clinical syndromes associated with FTLD are jointly classified as frontotemporal dementia (FTD) and include behavioral variant frontotemporal dementia (bvFTD), nonfluent-agrammatic primary progressive aphasia (nfvPPA), and semantic variant PPA (svPPA; left: l-svPPA and right: r-svPPA). All syndromes have differential impairment in behavioral (bvFTD; r-svPPA), executive (bvFTD; nfvPPA), and language (nfvPPA; svPPA) functions early in the disease course. With all three there is relative sparing of short-term memory and visuospatial abilities early on, and with the two language syndromes, nfvPPA and svPPA, behavior is also intact. Symptoms are associated with specific atrophy patterns, lending unique imaging signatures to each syndrome (frontal: bvFTD and nfvPPA; temporal: svPPA). Common proteinopathies involve accumulation of tau, transactive response DNA binding protein 43, and fusion in sarcoma protein. Parkinsonism presents in all syndromes, especially cases with tau pathology and *MAPT* or *GRN* mutations. nfvPPA often has corticobasal degeneration or progressive supranuclear palsy as the underlying neuropathological substrate. bvFTD co-occurs with motor neuron disease in ~15% of cases, and many such cases are due to *C9orf72* mutations. Other common genetic mutations in FTLD involve *GRN* and *MAPT*. Behavioral symptoms are best managed by selective serotonin reuptake inhibitors, while atypical antipsychotics should be used with caution given side effects. Promising etiologic treatments include anti-tau antibodies, antisense oligonucleotides, and progranulin enhancers.

Keywords

- frontotemporal dementia
- primary progressive aphasia
- behavior
- language
- parkinsonism
- diagnosis
- treatment

Frontotemporal lobar degeneration (FTLD) is defined as a pathologic endophenotype characterized by atrophy of the frontal and temporal lobes leading to three clinical syndromes with partially overlapping microscopic pathology. These are jointly called frontotemporal dementia (FTD) and include the behavioral variant frontotemporal dementia (bvFTD) and two types of the primary progressive aphasia (PPA),¹ the nonfluent-agrammatic (nfvPPA) and the semantic (svPPA). The three syndromes are associated with variable

impairment in behavioral, executive, language, and even motor functions early in the disease course. Each has a unique atrophy pattern on neuroimaging. Commonly, there is accumulation of tau, transactive response DNA binding protein 43 (TDP-43), fusion in sarcoma protein (FUS), and p62 dipeptides.²

In 2011, revised consensus criteria were created for both bvFTD and PPA to incorporate advances in imaging, pathology, and genetics, aiming to improve early diagnostic accuracy.^{3,4}

Issue Theme Atypical Parkinsonian Disorders; Guest Editors, Yvette Bordelon, MD, PhD, and Carlos Portera-Cailliau, MD, PhD

Copyright © 2014 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0034-1381735>.
ISSN 0271-8235.

Fig. 1 Frontotemporal lobar degeneration (FTLD) phenotypes, endophenotypes, and therapeutic associations. Common atrophy patterns, pathologies, and genetic mutations are depicted. Syndromes correlate well to gross atrophy patterns; similarly, genetic mutations correlate to specific proteinopathies. Line weights represent relative associations. ACC, anterior cingulate cortex; bvFTD, behavioral variant frontotemporal dementia; CBS, corticobasal syndrome; CHMP2B, charged multivesicular body protein 2b; DCTN1, dynactin 1; DLPFC, dorsolateral prefrontal cortex; FUS, fusion in sarcoma; GRN, progranulin; MAPT, microtubule associated protein tau; MND, motor neuron disease; nfvPPA, nonfluent-agrammatic PPA; OFC, orbitofrontal cortex; PPA, primary progressive aphasia; PSPS, progressive supranuclear palsy syndrome; svPPA, semantic variant PPA; TARDBP, transactive response DNA binding protein gene; TDP-43, transactive response DNA binding protein 43; UPS, ubiquitin proteasome system; VCP, valosin containing protein; VMPFC, ventromedial prefrontal cortex.

Early and accurate diagnosis, however, is not straightforward in FTLD, given the pathological convergence associated with specific clinical syndromes and the syndromic divergence within pathologies (► **Fig. 1**). Even family members with a single genetic mutation are phenotypically heterogeneous.

Historical Perspective and Epidemiology

In 1892, Arnold Pick described patients with presenile dementia, aphasia, and lobar atrophy.⁵ This entity was subsequently referred to as Pick disease, and the characteristic inclusion bodies associated with this condition, identified by Alois Alzheimer in 1911, were named Pick bodies in Pick's honor. In 1957, Delay, Brion, and Escourolle and in 1974 Constantinidis, Richard, and Tissot delineated the clinical and anatomical differences between Alzheimer disease (AD) and Pick disease, emphasizing that atrophy in Pick disease was frontally predominant, while in AD more posterior. Their classification schemas recognized that there were prominent extrapyramidal syndromes associated with Pick disease and that only a minority of cases had classic Pick bodies.^{6,7} In 1982, Marsel Mesulam identified aphasia syndromes in patients with left-predominant hemispheric atrophy,⁸ collectively termed PPA (now including nfvPPA, svPPA, and

logopenic variant PPA [lvPPA]).¹ Though Pick's first cases would currently be classified as svPPA of left-predominant atrophy (l-svPPA), in the past "Pick dementia" was considered synonymous to what is now called bvFTD. A right-predominant atrophy svPPA (r-svPPA) also exists and presents with early behavioral deficits, whereas its syndromic convergence and pathologic homology to l-svPPA allows both syndromes to be classified as svPPA (see below). Recent discoveries of specific proteinopathies (e.g., tau, TDP-43, FUS) as well as genetic mutations (e.g., GRN, MAPT, C9orf72) has opened avenues for new therapeutic interventions.^{9–16}

Epidemiologically, FTLD incidence is three to four cases per 100,000 person-years, with an estimated 20,000 to 30,000 cases in the United States at a given moment.¹⁷ It is the third most common cause of degenerative dementia after AD and dementia with Lewy bodies, accounting for 5 to 10% of all pathologically confirmed cases.¹⁸ Additionally, it is the second most common presenile dementia in patients younger than 65 years old after AD. Tau-positive cases tend to exhibit older disease onset and slower progression than TDP-43 and FUS FTLD subtypes.¹⁹ ► **Table 1** contains epidemiologic features of FTLD subtypes, recognizing that diagnosis in most studies was based on pre-2011 diagnostic criteria.

Table 1 Epidemiology of frontotemporal lobar degeneration (FTLD)^{19–22}

Clinical syndrome	Percentage of FTLD cases	Range of male percentage	Mean age of onset (range) ^a	Life expectancy in years from symptom onset (from diagnosis) ^b
bvFTD	54–69	53–70	58 (47–82)	with MND 6 (1) without MND 9 (5)
nvPPA	14–35	14–63	63 (42–79)	9 (4)
r-svPPA	6–10	44–80	62 (52–85)	12 (5)
l-svPPA	9–12	52–80	59 (52–80)	12 (5)

^aNo statistical difference.^bSignificantly shorter life expectancy only for bvFTD-MND cases.

Clinical Diagnosis

Frontotemporal lobar degeneration is caused by selective vulnerability of specific neuroanatomical networks. With bvFTD, nvPPA, and svPPA degeneration starts within a specific hub and spreads across the respective network in a prion-like manner, conferring unique clinical characteristics at each stage of the disease.^{23–25} As such, the most important clinical information lies in the temporal evolution of symptoms, and by extension, their neuroanatomical representation, allowing the physician to create a mental map of brain atrophy progression. The diagnostic process aims to identify the phenotypic syndrome (i.e., bvFTD vs. nvPPA vs. svPPA vs. other dementia or nondementia syndromes), and then predict the most likely proteinopathy and possible genetic mutation (►Figs. 1,2, and ►Tables 2,3).³¹ This approach can provide a more accurate prognosis, and as molecule-specific therapies develop, more tailored treatment.

There are distinct differences between patients with right-versus left-sided disease. Right-predominant atrophy patients (bvFTD; r-svPPA) tend to be emotionally cold and distant, often disrupting family relationships, and present with behavioral disturbances that are often misinterpreted as psychiatric symptoms. Left-predominant atrophy patients mainly present with language impairments (►Table 2).

bvFTD is dominated by behavioral symptoms. Because early degeneration affects the paralimbic structures of the ventromedial prefrontal cortex (VMPFC), anterior cingulate cortex (ACC), and anterior insula, early symptoms involve social disinhibition, lack of motivation (apathy), and loss of empathy.^{31,34} Often, family members believe the patient has lost interest in the family, is depressed, or suffers from a psychiatric disorder. Patients are often distractible and it is not uncommon for them to lose their jobs. Symptoms of disinhibition may range from inappropriate (e.g., hugging people in the street) to antisocial (e.g., commenting on peoples' weight). Lack of empathy is striking, and patients may ignore acute health issues of their spouses. As selective degeneration spreads to the temporal lobes, particularly the right, mental rigidity and unique eating habits start to emerge (e.g., eating only single-colored food). Some patients may

develop cravings for carbohydrate-rich food such as sweets and chips. Compulsive behaviors can range from simple repetitive movements (e.g., tapping, coughing) to more complex compulsions (e.g., hoarding, collecting, cleaning, eating specific foods at specific times). As the dorsolateral prefrontal cortex (DLPFC) degenerates, executive abilities falter, with working memory impairment, difficulty with set-shifting and generation of ideas or alterations in attention.³⁶ Usually, patients have poor insight into their deficits, distort their history, and admit to having bvFTD as a matter-of-fact based on others' reports, rather than appreciating that something is amiss. This may relate to noso-adiaphoria (anosodiaphoria) rather than noso-agnosia (anosognosia).³⁷

A slowly progressive bvFTD exists, termed "phenocopy" by Chris Kipps and John Hodges, which differs from the classic form due to decades-long progression and male predominance.³⁸ It is indistinguishable from the classic form based on simple diagnostic criteria, although measures of executive and functional impairment tend to be less severe in the phenocopy cases and atrophy may be mild, or even absent. Some of these patients are primarily psychiatric, although *C9orf72* mutations may also be responsible for the syndrome.³⁹

One in seven bvFTD patients develop MND,²² which has a similar phenotype to sporadic MND, although often lower limb muscles seem to be spared early on. Because bvFTD-MND has strong pathological associations with TDP-43 type B and *C9orf72* (and some other) mutations (►Table 3), it is often approached separately from bvFTD without MND. There is evidence of a *C9orf72* mutation founder effect from 6,300 years ago in the Western world, making it the most common genetic cause of bvFTD-MND and accounting for about a third of familial cases, but these *C9orf72* appear to be rare in south and eastern Asia.^{13,14,44} *C9orf72* mutations are large hexanucleotide repeat expansions (GGGGCC) in the intron region of chromosome 9, which leads to RNA nuclear accumulation and suppression of gene expression. The disease phenotype does not seem to depend on repeat length and there is only preliminary evidence that longer repeat sizes, specifically in the cerebellum, have a negative impact on survival.⁴⁵

Fig. 2 Syndrome natural history in frontotemporal lobar degeneration.^{26–30} Common cognitive, behavioral, and atrophic patterns with disease progression; see text for details. Graphs depict relative qualitative symptom severity with disease progression. Speed of disease progression in bvFTD is more variable than other syndromes, with Clinical Dementia Rating (CDR) Scale scores ranging from 0.5 to 3 at 6 years from symptom onset.

nfvPPA is the prototypical syndrome with impairments in language structure and praxis. Characteristic deficits include nonfluent output, agrammatism, and apraxia of speech (AOS).^{1,3} Patients understand the meaning of individual words or objects, but have trouble with more complex sentences. The neuroanatomical network affected by degeneration includes the dominant frontal operculum, its con-

nections to the supplementary motor area (SMA) through the frontal aslant tract, the premotor area, and the insular cortex.^{28,46} Thus, early symptoms are slowness of speech, word-finding difficulties, and decreased word output and phrase length. Apraxia of speech (i.e., an articulation planning deficit) emerges as a disconnection between the frontal operculum and the SMA, associated with aslant tract

Table 2 Syndrome phenotypes and endophenotypes^{4,32–35}

Clinical syndrome	Characteristic earliest symptoms	Early patient or family concerns	Behavioral features	Cognitive features	Motor features	Earliest atrophic areas	Common pathology
bvFTD	Apathy Disinhibition Loss of self and other awareness	Midlife crisis Mood disorder Psychosis	Apathy (54–96%) Disinhibition (73%) Lack of empathy (49–75%) Compulsions (67%) Loss of awareness (65%) Hyperorality (59%) Anxiety (56%)	Poor (lexical) generation Poor episodic memory Poor set-shifting	MND (~15%) Parkinsonism (~20%)	Anterior cingulate Frontoinsular (R > L)	most heterogeneous tau $\cong$ TDP-43 few FUS and UPS tau: 3R or 4R TDP-43: esp. Type A, B, or D
nvPPA	Nonfluent speech AOS	Word-finding difficulties Slow or slurred speech	Later in course: Apathy and disinhibition Restlessness Aggression	Language impairment: nonfluent, agrammatic, AOS Executive impairment Poor episodic memory	Strong association with PSPS and CBS	Dominant FO Premotor SMA Anterodorsal insula	tau (esp. 4R) > TDP-43 AD pathology (30%)
r-svPPA	Emotional detachment Mental rigidity Atypical depression Irritability Bizarre dressing	“Cold and distant” Exaggeration of personality traits Mood disorder	Disinhibition (74%) Eating disorders (52%) Sleep disorders (52%) Loss of empathy (49%) Depression (44%)	Prosopagnosia Poor emotional recognition Word obsessions Poor semantic memory Increased visual alertness	Extremely rare Few cases of MND	Right anterior temporal Amygdala	TDP-43 (Type C) rare tau AD pathology (33%)
l-svPPA	Anomia Loss of word meaning	Word-finding difficulties	Eating disorders (52%) Sleep disorders (52%) Depression (44%)	Semantic anomia Surface dyslexia Verbal episodic memory loss	Extremely rare Few cases of MND	Left anterior temporal Amygdala	TDP-43 (Type C) rare tau AD pathology (33%)

Abbreviations: AOS, apraxia of speech; CBS, corticobasal syndrome; FO, frontal operculum; MND, motor neuron disease; PSPS, progressive supranuclear palsy syndrome; SMA, supplementary motor area.

Table 3 Clinicopathological associations^{2,9–16,40–43}

Clinical syndrome	Characteristic clinicopathological associations
bvFTD	<p>tau Parkinsonism common (including CBS); “parietal” symptoms (e.g., acalculia) more common than in ubiquitin cases Symmetric frontal atrophy involving temporal lobes; more prominent striatal atrophy and white matter abnormalities than ubiquitin cases <i>MAPT</i> mutations (Chromosome 17)</p> <p>TDP-43 type A (see below)</p> <p>TDP-43 type B Associated with bvFTD-MND; parkinsonism (rarely CBS) Mildly asymmetric frontal atrophy and parietal, pulvinar and cerebellar atrophy <i>C9orf72</i> mutations (Chromosome 9; Baltic ancestry; most common known genetic cause) Less common genes: <i>TARDBP</i> (Italian/French ancestry; parkinsonism and MND), <i>DCTN1</i> (Perry syndrome)</p> <p>TDP-43 Type D bvFTD (± MND), IBM and Paget disease of the bone; parkinsonism uncommon <i>VCP</i> gene (Chromosome 9)</p> <p>FUS Younger onset (30s to 40s); associated with bvFTD-MND; psychotic features (up to 36%) <i>FUS</i> mutations (Chromosome 16)</p> <p>UPS <i>CHMP2B</i> mutations (Chromosome 3; Denmark)</p> <p>Other genes related to TDP-43 pathology <i>UBQLN2</i> (MND, X-linked, mean onset 30s to 40s), <i>OPTN</i> (MND), <i>hnRNPA1</i>, and <i>A2/B1</i> (IBM and Paget disease)</p>
nvfPPA	<p>TDP-43 type A Parkinsonism frequent (including CBS) Asymmetric atrophy of dorsolateral frontoparietal lobes and basal ganglia <i>GRN</i> mutations (Chromosome 17)</p> <p>tau Strongly associated with AOS Usually CBD or PSP</p>
l-svPPA	<p>TDP-43 Type C Movement disorders uncommon; coexistence of autoimmune diseases and left-handedness Left-predominant anterior temporal atrophy Almost exclusive pathology; rarely genetic</p>
r-svPPA	<p>TDP-43 Type C Movement disorders uncommon; coexistence of autoimmune diseases and left-handedness Right-predominant anterior temporal atrophy Almost exclusive pathology; rarely genetic</p>

Abbreviations: AOS, apraxia of speech; CBD, corticobasal degeneration; CBS, corticobasal syndrome; *CHMP2B*, charged multivesicular body protein 2b; *DCTN1*, dynactin 1; *FUS*, fusion in sarcoma; *GRN*, progranulin; *hnRNPA*, heterogeneous nuclear ribonucleoprotein; IBM, inclusion body myositis; MND, motor neuron disease; *OPTN*, optineurin; PSP, progressive supranuclear palsy; *TARDBP*, TAR DNA-binding protein; *UBQLN2*, ubiquilin 2; UPS, ubiquitin proteasome system; *VCP*, valosin containing protein.

degeneration.⁴⁶ In contrast, agrammatism, which in addition to simplified phrases is defined by omission of function words and inflections, develops with progressive atrophy of the left frontal operculum and DLPFC, but also of the insula, anterosuperior temporal cortex, as well as white matter degeneration of the dominant cingulum and corpus callosum.⁴⁷ Emergence of phonemic paraphasias (e.g., phoneme transpositions, additions, omissions) relates to progressive atrophy of the insula, anterior cingulate, premotor cortex, and SMA.⁴⁷ In contrast to bvFTD, nvfPPA patients often become aware of their deficits prior to others and maintain a proper social decorum. As the disease moves into the contralateral frontal regions, some nvfPPA patients eventually develop

behavioral disturbances. Finally, nvfPPA often coincides with corticobasal syndrome (CBS) or progressive supranuclear palsy syndrome (PSPS), in which a 4-repeat tauopathy is probable, although CBS may also result from TDP-43 Type A pathology with or without *GRN* mutations (► **Table 3**).

Both svPPA syndromes have semantic knowledge deficits with intact speech fluency, but differ in that early symptoms in l-svPPA pertain to lexical meaning loss, whereas in r-svPPA to loss of emotional meaning and knowledge about faces.⁴⁸ Symptoms correlate to early atrophy of the anterior temporal pole, which serves as a hub for semantic knowledge and from which degeneration spreads.^{25,26,28} Disease spreads to frontal areas once the uncinate fasciculus becomes affected, highlighting its

role in semantic processing,⁴⁶ while there is accompanying atrophy of the insula and anterior hippocampus.^{26,28}

Early features of l-svPPA include word-finding difficulties, especially of nouns rather than verbs. Gradually, patients substitute specific words with superordinate categories (e.g., *animal* for *cat*), and eventually most nouns are called *things*. At later stages, loss of word meaning becomes very pronounced and patients have trouble recognizing what is shown to them and its general purpose. In contrast, early features of r-svPPA are behavioral, in keeping with an underlying right-predominant atrophy, while language problems present later in its course.^{20,48} r-svPPA manifests with early emotional detachment, lack of empathy, and diagnosis is often delayed because symptoms are misinterpreted as psychiatric or worsening of chronic personality traits. Some patients' symptoms begin with impairment recognizing familiar faces, and evolve into a severe deficit in facial perception.

At intermediate svPPA stages, degeneration spreads to the opposite hemisphere and the two svPPA subtypes merge at the syndromic and atrophic level (►Fig. 2). In clinic, patients may show surface dyslexia, in which they incorrectly read irregularly-written low-frequency words (e.g., *yacht*). svPPA patients develop an interest for visually appealing objects, which may express itself as compulsions or artistic creativity. De novo creativity is a fascinating feature in FTLT, especially l-svPPA, which may emerge a few years prior to the onset of disabling symptoms, and is probably caused by abolishment of interhemispheric inhibition.

Parkinsonism in Frontotemporal Lobar Degeneration

Approximately one-fifth of bvFTD patients have parkinsonism on their first clinic visit.³⁵ Parkinsonian features are more common in bvFTD and nfvPPA patients, often those with tau pathology, *MAPT* and *GRN* mutations, and at later disease stages, whereas its presence does not affect survival (►Tables 2 and 3).^{22,35} Most bvFTD cases have an akinetic-rigid form (60%) and the rest (40%) are tremor-predominant. Movement disorders rarely accompany svPPA.

Corticobasal syndrome and PSPS are often considered as clinical diagnoses when parkinsonism is present early in FTLT. Unlike classic Parkinson disease, where rigidity, tremor, and bradykinesia dominate the early phases, PSPS presents with axial rigidity, relative sparing of the arms, and lack of tremor. Presence of early falls and a supranuclear gaze palsy is typical for PSPS. Corticobasal syndrome is characterized by apraxia (especially of the feet), alien limb phenomenon, inattention, dystonia, and myoclonus. Cortical symptoms (e.g., aphasia) overlap with those observed in bvFTD and nfvPPA.^{49,50} Corticobasal syndrome and PSPS are designed to predict 4-repeat tauopathies (i.e., corticobasal degeneration [CBD] and progressive supranuclear palsy [PSP], respectively). Although clinicopathological association is high for PSPS, CBS criteria have not been highly predictive and up to 50% of cases have alternative pathologies (e.g., AD [23%] and TDP-43 [13%]).⁵¹ As a result, CBS criteria were recently revised, though their clinical utility and diagnostic accuracy remains to be seen.⁴⁹

Parkinsonism in FTLT can also be due to specific genetic mutations. Two such genes are *MAPT* and *GRN*, which are 1.7 Mb apart on chromosome 17. *GRN* mutation deficits caused by progranulin haploinsufficiency have a mean age at onset of 59 years; *MAPT* mutations tend to present at an earlier age with a mean age at onset of 49 years. Life expectancy from the time of diagnosis is approximately 7 years for both. Shared signs of parkinsonism are rigidity and bradykinesia without a resting tremor. Furthermore, *GRN* mutation patients have asymmetric parkinsonism earlier in their course, and often display CBS, whereas *MAPT* mutation patients have a more symmetric akinetic-rigid parkinsonism and less typically exhibit CBS. On MRI, *GRN* mutation patients often show asymmetric atrophy that extends to the parietal lobes, and white matter signal abnormalities are common. In *MAPT* mutation cases, atrophy is more symmetric and parietal atrophy is not typically present.⁵² Another gene associated with parkinsonism and often MND is *TARDBP*,⁵³ a rare mutation that has been reported in patients of Italian-French ancestry. In addition to rigidity and bradykinesia, rest tremor is more prevalent than in other FTLT-related mutations. *C9orf72* and *FUS* mutations are also associated with parkinsonism, but, more typically, MND dominates their motor symptoms.

An interesting, yet unique, parkinsonism association in FTLT is the amyotrophic lateral sclerosis-Parkinson-dementia complex (ALS-PDC) of Guam.⁵⁴ ALS-PDC is strongly familial, but no genetic or environmental cause has been verified, while its prevalence has gradually declined. Clinically, there is rigidity, bradykinesia, and a nondisabling action-induced tremor. Finally, linear pigment retinal epitheliopathy occurs in 56% of cases compared with 16% of controls.

Additional Studies

In addition to obtaining a history of present illness and performing a physical examination, which provide the most useful diagnostic information, workup for suspected FTLT should include neuropsychological testing and structural brain MRI. Neuropsychological testing allows confirmation of historically reported cognitive deficits. It may not be significantly abnormal in the early stages of bvFTD or r-svPPA because early symptoms are mostly behavioral. In nfvPPA and l-svPPA specific tests of language are required. Generally, bvFTD patients have deficits in executive control, svPPA patients have language difficulties, evident on confrontation naming, and nfvPPA patients perform poorly on fluent output, word generation, and understanding of complex syntax comprehension.^{3,36} Tests of social cognition focused around social perception and behavior are helpful and may emerge in FTLT prior to the onset of changes in executive control.⁵⁵

One cornerstone of the FTLT workup is structural brain MRI. As reflected in ►Fig. 2 and ►Tables 2 and 3, atrophy patterns vary between syndromes and even between genetic mutations within syndromes.^{28,31,40} Clinicians should look for these changes in MRI sequences themselves and should not rely solely on the radiologist's impression, as radiologists often fail to comment on atrophy patterns. Additionally, MRI helps rule out other causes of cognitive and behavioral

Table 4 Criteria for the diagnosis of bvFTD, nvPPA, and svPPA^{1,3,4}

Syndrome	Possible/clinical diagnosis	Probable/imaging supported diagnosis ^b	Definite/pathologically or genetically proven diagnosis	Exclusionary criteria
bvFTD	At least 3 of the following: <ul style="list-style-type: none"> • Early^a behavioral disinhibition • Early apathy or inertia • Early lack of empathy or sympathy • Early perseverations, stereotypies or compulsions • Dietary habit changes or hyperorality • Executive-predominant deficits on neuropsychological testing with relative sparing of memory and visuospatial skills 	All of the following: <ul style="list-style-type: none"> • Meets possible criteria • Significant decline per informant, or CDR, or FAQ • Imaging consistent with bvFTD (frontal and/or anterotemporal) 	All of the following: <ul style="list-style-type: none"> • Meets possible OR probable criteria • Histopathological evidence of FTLD and/or presence of known pathogenic mutation 	<ul style="list-style-type: none"> • Deficits are not better explained by alternative diagnosis (degenerative, nondegenerative, or psychiatric)
nvPPA ^d	At least one of the following: <ul style="list-style-type: none"> • Agrammatism • Effortful, halting speech with inconsistent sound errors (AOS) At least two of the following: <ul style="list-style-type: none"> • Impaired comprehension of syntactically complex sentences • Spared single-word comprehension • Spared object knowledge 	All of the following: <ul style="list-style-type: none"> • Meets possible/clinical criteria • Imaging consistent with nvPPA (left posterior frontoinsula) 	All of the following: <ul style="list-style-type: none"> • Meets possible OR probable criteria • Histopathological evidence of specific pathology^c and/or presence of known pathogenic mutation 	<ul style="list-style-type: none"> • Deficits are not better explained by alternative diagnosis (nondegenerative, or psychiatric) • Prominent initial deficits are not memory, visuospatial, or behavioral
svPPA ^d	All of the following: <ul style="list-style-type: none"> • Impaired confrontation naming • Impaired single-word comprehension At least 3 of the following: <ul style="list-style-type: none"> • Impaired object knowledge • Surface dyslexia or dysgraphia • Spared repetition • Spared grammar and motor speech production 	All of the following: <ul style="list-style-type: none"> • Meets possible/clinical criteria • Imaging consistent with svPPA (anterior temporal lobe) 	All of the following: <ul style="list-style-type: none"> • Meets possible OR probable criteria • Histopathological evidence of specific pathology^c and/or presence of known pathogenic mutation 	<ul style="list-style-type: none"> • Deficits are not better explained by alternative diagnosis (nondegenerative, or psychiatric) • Prominent initial deficits are not memory, visuospatial, or behavioral

Abbreviations: AOS, apraxia of speech; CDR, Clinical Dementia Rating Scale; FAQ, Functional Activities Questionnaire; FTLD, frontotemporal lobar degeneration; PET, positron emission tomography; SPECT, single-photon emission computed tomography.

^aApproximately within the first 3 years from symptom onset.

^bImaging refers to structural magnetic resonance imaging atrophy, PET hypometabolism, or SPECT hypoperfusion.

^cSpecific pathology in 2011 PPA (primary progressive aphasia) criteria may be tau, TDP-43, Alzheimer disease, or other proteinopathy.

^dBoth nvPPA and svPPA must satisfy PPA criteria by Mesulam¹ with language impairment being the most prominent, disabling, and earliest symptom.

impairment, such as tumors, vascular disease, prion, and paraneoplastic disorders; hence the need for sequences such as diffusion weighted imaging, fluid attenuated inversion recovery, and gradient echo.^{28,31} In contrast to MRI, there are no characteristic changes on electroencephalography, other than mild frontal slowing.

Functional resting state imaging in FTLD, such as metabolism-associated positron emission tomography (PET), single-photon emission computed tomography, and functional MRI, highlights impairments to vulnerable brain networks associated with behavioral and cognitive deficits (i.e., frontal and anterior temporal lobes).³⁵ A conceptually similar approach

Table 5 Pharmacological treatments^{64–82}

Medication	Dose	Population	Study designs	Combined study outcome	Side effects
Trazodone	Up to 300 mg daily	bvFTD	DB-CO-RCT	Improved behavior ^a	Fatigue, dizziness, hypotension
Fluvoxamine	50–150 mg daily	bvFTD, svPPA	OL	Improved stereotypies	Appetite loss
Paroxetine	Up to 40 mg daily	bvFTD	OL, OL-RCT, DB-CO-RCT	No definite behavioral benefit Improved mood, compulsions, and eating disorders	Well tolerated
Fluoxetine	20 mg daily	bvFTD	OL	Improved mood, compulsions, and eating disorders	Well tolerated
Sertraline	50–125 mg daily	bvFTD	OL-CT, OL	Improved stereotypies	Well tolerated
Citalopram	40 mg daily	bvFTD	OL	Improved behavior	Well tolerated
Donepezil	Up to 10 mg daily	bvFTD	OL, DC	No benefit	Worse behavioral symptoms
Galantamine	Up to 24 mg daily	bvFTD, PPA	OL to DB-RCT	No benefit	Mild GI symptoms
Rivastigmine	Up to 9 mg daily	bvFTD	OL-CT	Improved behavior	Well tolerated
Quetiapine	Up to 150 mg total daily dose	bvFTD, nvfPPA, svPPA	DB-CO-RCT	No definite benefit	Somnolence
Olanzapine	Up to 10 mg daily	bvFTD	OL	Improved agitation and anxiety	Somnolence, mild GI symptoms
Bromocriptine	Up to 7.5 mg 3 times daily	PPA	DB-CO-RCT	No benefit	Rare frustration intolerance
Methylphenidate	40 mg once	bvFTD	DB-CO-CT	Improved decision making within a few hours	Non-significant blood pressure increase
Dextroamphetamine	20 mg total daily dose	bvFTD, nvfPPA, svPPA	DB-CO-RCT	Improved behavior	Well tolerated
Memantine	Up to 20 mg daily	bvFTD, nvfPPA, svPPA	OL, DB-RC	No benefit	Well tolerated

Abbreviations: CO, crossover; CT, control trial; DB, double blind; DC, discontinuation of treatment; GI, gastrointestinal; OL, open-label; RCT, randomized control trial.

^aImproved behavior usually corresponds to neuropsychiatric inventory scores or refers to irritability, agitation, depression, and eating disorders.

uses diffusion tensor imaging, which represents the structural integrity of white matter tracts connecting brain hubs. White matter tracts are affected early in the disease process, even in presymptomatic FTLT mutation carriers, and may provide even better diagnostic accuracy than volumetric MRI.^{56,57}

Fluid biomarkers, such as blood and cerebrospinal fluid (CSF) have been extensively studied in FTLT. Testing for genetic mutations is useful if an autosomal dominant mutation is suspected (►Table 3). A risk factor for FTLT-tau, especially CBD and PSP, is histone 1 haplotype.⁵⁸ In contrast, minor *TMEM106B* allele homozygosity protects *GRN* and *C9orf72* mutation carriers.^{59,60} The best studied CSF biomarker is the tau: A β _{1–42} ratio, which is significantly lower in FTLT than AD patients.⁶¹

Molecular PET is useful to test for the presence of amyloid pathology. Current guidelines recommend its use by a dementia expert (1) in patients younger than 65 years old, (2) in persistent or progressive unexplained mild cognitive impairment, and (3) in atypical or mixed-dementia presentations.⁶² Thus, it is helpful in differentiating AD from bvFTD, or lvPPA from nvPPA, or to identify dual pathology. Tau imaging will soon be available to search for tau-positive forms of FTLT.⁶³ Currently, there is no TDP-43 or FUS PET.

Diagnostic Criteria

Frontotemporal lobar degeneration diagnostic criteria were revised in 2011 for both bvFTD and PPA, aiming to improve diagnostic accuracy (►Table 4).^{3,4} Nonetheless, there is still room for criteria improvement because diagnostic accuracy and interrater reliability is imperfect. In time, it is likely that criteria will incorporate molecular PET, improving direct syndrome-to-pathology diagnostic associations (►Fig. 1), while in parallel addressing multiple copathologies (e.g., AD and FTLT).

Treatment

►Table 5 lists symptomatic treatments tested in FTD trials. Prior etiologic treatments have either proven toxic or non-efficacious.⁸³ For more details on FTD therapies, see also the review in the current issue by Tsai and Boxer, Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes. In general, selective serotonin reuptake inhibitors are mildly beneficial for compulsions and eating disorders. Dopaminergic medications have no definite behavioral benefit. Recent trials do not support the use of memantine, and cholinesterase inhibitors seem to worsen behavior. Atypical antipsychotics should be used with caution only in cases of severe agitation given their extrapyramidal side effects. Levodopa may be considered in parkinsonism, especially where tau pathology or *MAPT* mutations are suspected, but a sustained response is rarely present.

A promising etiologic therapy focuses on halting tau spread using anti-tau antibodies, which in animal models decrease protein accumulation and improve behavior.⁸⁴ Antisense oligonucleotides are being studied in *C9orf72* mutations.⁸⁵ There is a single report of steroid treatment improving symptoms in svPPA, highlighting its association

Table 6 Foundations and Support Groups

<p>Association for Frontotemporal Degeneration (AFTD) Radnor Station Building 2, Suite 320, 290 King of Prussia Road, Radnor, PA 19087, USA Telephone: +1-267-514-7221 or HelpLine: +1-866-507-7222 (toll free) http://www.theaftd.org</p>
<p>Consortium for Frontotemporal Dementia Research – The Bluefield Project to Cure Frontotemporal Dementia 1650 Owens Street, Room 205, San Francisco, CA 94158, USA http://www.bluefieldproject.org/contact-us</p>
<p>FRONTIER Frontotemporal Dementia Research Group NeuRA, PO Box 1165, Randwick NSW 2031, Australia Telephone: +61-2-9399-1000 https://www.neura.edu.au/contact-us</p>
<p>Tau Consortium http://tauconsortium.org</p>
<p>The Foundation for PSP CBD and Related Brain Diseases (CurePSP) 30 E. Padonia Road, Suite 201, Timonium, MD 21093, USA Telephone: +1-410-785-7004 or +1-800-457-4777 (toll free) http://www.psp.org</p>
<p>National Institute of Neurological Disorders and Stroke (NINDS) Patient Recruitment and Public Liaison Office: +1-800-411-1222 (toll free) http://www.ninds.nih.gov/disorders/picks/picks.htm</p>
<p>The Frontotemporal Dementia Support Group (United Kingdom) The National Brain Appeal, Box 123, Queen Sq, London, WC1N 3BG, UK Regional contact information: http://www.ftdsg.org/Regional_contacts</p>
<p>Frontotemporal Dementia Caregiver Support Center http://ftdsupport.com</p>
<p>Family Caregiver Alliance 785 Market Street, Suite 750, San Francisco, CA 94103, USA Telephone: +1-415-434-3388 or +1-800-445-8106 http://www.caregiver.org</p>
<p>Neil L. Radin Caregivers Relief Foundation 4404 Aberdeen Lane Blackwood, Blackwood, NJ 08012, USA Telephone: +1-215-205-3162</p>
<p>FTD Support Forum http://ftdsupportforum.com</p>

to autoimmunity.⁸⁶ Finally, treatments that raise progranulin levels are in development for *GRN* mutations.⁸³

Nonpharmacological management of FTLT is as important as are pharmacological therapies. Family education and respite, a regular sleep schedule, social worker involvement, driving evaluation, exercise, and speech therapy can improve patients' and families' quality of life. Thus, a multidisciplinary dementia clinic is the optimal setting for management of FTLT. ►Table 6 contains information on foundations and support groups for FTLT.

Acknowledgments

Funding support for this work was provided through a Hellman Family Fellowship, the Consortium for Frontotemporal Dementia Research, the Tau Consortium, and NIH grant NIA-PPG P01-AG1972403.

References

- Mesulam MM. Primary progressive aphasia. *Ann Neurol* 2001; 49(4):425–432
- Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. *Nat Rev Neurol* 2012;8(8):423–434
- Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology* 2011; 76(11):1006–1014
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134(Pt 9):2456–2477
- Pick A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie. *Prager Medicinische Wochenschrift* 1892;17:165–167
- Constantinidis J, Richard J, Tissot R. Pick's disease. Histological and clinical correlations. *Eur Neurol* 1974;11(4):208–217
- Delay J, Brion S, Escourolle R. Limites et conception actuelle de la maladie de Pick; son diagnostic différentiel. *Ann Med Psychol (Paris)* 1957;115(4):609–634
- Mesulam MM. Slowly progressive aphasia without generalized dementia. *Ann Neurol* 1982;11(6):592–598
- Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 1998;393(6686):702–705
- Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. *Proc Natl Acad Sci U S A* 1998;95(13):7737–7741
- Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 2006;442(7105):916–919
- Cruts M, Gijselink I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 2006;442(7105):920–924
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 2011;72(2): 245–256
- Renton AE, Majounie E, Waite A, et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 2011;72(2): 257–268
- Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* 2006;351(3):602–611
- Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 2006;314(5796):130–133
- Knopman DS, Roberts RO. Estimating the number of persons with frontotemporal lobar degeneration in the US population. *J Mol Neurosci* 2011;45(3):330–335
- Snowden JS, Neary D, Mann DM. Frontotemporal dementia. *Br J Psychiatry* 2002;180:140–143
- Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. *Neurology* 2003;61(3):349–354
- Ioannidis P, Konstantinopoulou E, Maiovis P, Karacostas D. The frontotemporal dementias in a tertiary referral center: classification and demographic characteristics in a series of 232 cases. *J Neurol Sci* 2012;318(1-2):171–173
- Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. *Arch Neurol* 2005;62(6):925–930
- Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. *Neurology* 2005;65(5):719–725
- Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. *Neuron* 2009;62(1):42–52
- Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Transcellular propagation of tau aggregation by fibrillar species. *J Biol Chem* 2012;287(23):19440–19451
- Guo CC, Gorno-Tempini ML, Gesierich B, et al. Anterior temporal lobe degeneration produces widespread network-driven dysfunction. *Brain* 2013;136(Pt 10):2979–2991
- Brambati SM, Rankin KP, Narvid J, et al. Atrophy progression in semantic dementia with asymmetric temporal involvement: a tensor-based morphometry study. *Neurobiol Aging* 2009;30(1):103–111
- Seeley WW, Bauer AM, Miller BL, et al. The natural history of temporal variant frontotemporal dementia. *Neurology* 2005; 64(8):1384–1390
- Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. *Ann Neurol* 2004;55(3):335–346
- Lu PH, Mendez MF, Lee GJ, et al. Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. *Dement Geriatr Cogn Disord* 2013;35(1-2):34–50
- Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. *Arch Neurol* 2008;65(2):249–255
- Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. *Neurology* 2002;58(2):198–208
- Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. *Ann Neurol* 2006; 59(1):156–165
- Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. *Cogn Behav Neurol* 2004;17(4):185–190
- Liu W, Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. *Neurology* 2004;62(5):742–748
- Le Ber I, Guedj E, Gabelle A, et al; French research network on FTD/FTD-MND. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. *Brain* 2006;129(Pt 11):3051–3065
- Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. *Cogn Behav Neurol* 2003;16(4):211–218
- Mendez MF, Shapira JS. Loss of emotional insight in behavioral variant frontotemporal dementia or "frontal anosodiaphoria". *Conscious Cogn* 2011;20(4):1690–1696
- Kipps CM, Hodges JR, Hornberger M. Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the 'bvFTD phenotype syndrome'. *Curr Opin Neurol* 2010;23(6):628–632
- Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. *J Neurol Neurosurg Psychiatry* 2012;83(4):358–364
- Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. *Curr Opin Neurol* 2011;24(6):542–549
- Janssens J, Van Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. *Hum Mol Genet* 2013;22(R1):R77–R87
- Miller ZA, Rankin KP, Graff-Radford NR, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. *J Neurol Neurosurg Psychiatry* 2013;84(9):956–962

- 43 Miller ZA, Mandelli ML, Rankin KP, et al. Handedness and language learning disability differentially distribute in progressive aphasia variants. *Brain* 2013;136(Pt 11):3461–3473
- 44 Smith BN, Newhouse S, Shatunov A, et al. The C9ORF72 expansion mutation is a common cause of ALS+/–FTD in Europe and has a single founder. *Eur J Hum Genet* 2013;21(1):102–108
- 45 van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. *Lancet Neurol* 2013;12(10):978–988
- 46 Catani M, Mesulam MM, Jakobsen E, et al. A novel frontal pathway underlies verbal fluency in primary progressive aphasia. *Brain* 2013;136(Pt 8):2619–2628
- 47 Ash S, Evans E, O'Shea J, et al. Differentiating primary progressive aphasias in a brief sample of connected speech. *Neurology* 2013;81(4):329–336
- 48 Thompson SA, Patterson K, Hodges JR. Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. *Neurology* 2003;61(9):1196–1203
- 49 Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology* 2013;80(5):496–503
- 50 Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology* 1996;47(1):1–9
- 51 Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. *Ann Neurol* 2011;70(2):327–340
- 52 Boeve BF, Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). *Arch Neurol* 2008;65(4):460–464
- 53 Borroni B, Archetti S, Del Bo R, et al. TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. *Rejuvenation Res* 2010;13(5):509–517
- 54 Lee SE. Guam dementia syndrome revisited in 2011. *Curr Opin Neurol* 2011;24(6):517–524
- 55 Elamin M, Pender N, Hardiman O, Abrahams S. Social cognition in neurodegenerative disorders: a systematic review. *J Neurol Neurosurg Psychiatry* 2012;83(11):1071–1079
- 56 Santillo AF, Mårtensson J, Lindberg O, et al. Diffusion tensor tractography versus volumetric imaging in the diagnosis of behavioral variant frontotemporal dementia. *PLoS ONE* 2013;8(7):e66932
- 57 Dopfer EG, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. *Neurology* 2013;80(9):814–823
- 58 Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. *Neurology* 2001;56(12):1702–1706
- 59 Finch N, Carrasquillo MM, Baker M, et al. TMEM106B regulates progranulin levels and the penetrance of FTL in GRN mutation carriers. *Neurology* 2011;76(5):467–474
- 60 van Blitterswijk M, Mullen B, Nicholson AM, et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. *Acta Neuropathol* 2014;127(3):397–406[Epub ahead of print]
- 61 Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. *Neurology* 2008;70(19 Pt 2):1827–1835
- 62 Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's association. *J Nucl Med* 2013;54(3):476–490
- 63 Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. *Neuron* 2013;79(6):1094–1108
- 64 Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanctôt KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. *Am J Geriatr Psychiatry* 2012;20(9):789–797
- 65 Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. *J Clin Psychiatry* 1997;58(5):212–216
- 66 Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. *Int J Geriatr Psychiatry* 2002;17(4):391–392
- 67 Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. *Am J Alzheimers Dis Other Dement* 2003;18(4):205–214
- 68 Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. *Eur Neurol* 2003;49(1):13–19
- 69 Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. *Drugs Aging* 2004;21(14):931–937
- 70 Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. *Mov Disord* 2005;20(6):742–745
- 71 Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. *Dement Geriatr Cogn Disord* 2004;17(3):117–121
- 72 Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dement Geriatr Cogn Disord* 2004;17(4):355–359
- 73 Mendez MF, Shapira JS, McMurtry A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. *Am J Geriatr Psychiatry* 2007;15(1):84–87
- 74 Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. *Geriatr Gerontol Int* 2013;13(2):506–507
- 75 Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. *Dement Geriatr Cogn Disord* 2008;25(2):178–185
- 76 Huey ED, Garcia C, Wassermann EM, Tierney MC, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. *J Clin Psychiatry* 2008;69(12):1981–1982
- 77 Reed DA, Johnson NA, Thompson C, Weintraub S, Mesulam MM. A clinical trial of bromocriptine for treatment of primary progressive aphasia. *Ann Neurol* 2004;56(5):750
- 78 Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. *Neuropsychopharmacology* 2006;31(3):651–658
- 79 Diehl-Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. *Int J Geriatr Psychiatry* 2008;23(7):754–759
- 80 Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2013;12(2):149–156
- 81 Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. *Alzheimer Dis Assoc Disord* 2009;23(3):211–217
- 82 Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. French research network on frontotemporal dementia. Memantine in behavioral variant frontotemporal dementia: negative results. *J Alzheimers Dis* 2011;23(4):749–759
- 83 Boxer AL, Gold M, Huey E, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for

- frontotemporal degeneration drug development. *Alzheimers Dement* 2013;9(2):176–188
- 84 Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. *Neuron* 2013;80(2):402–414
- 85 Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. *Proc Natl Acad Sci U S A* 2013;110(47):E4530–E4539
- 86 Decker DA, Heilman KM. Steroid treatment of primary progressive aphasia. *Arch Neurol* 2008;65(11):1533–1535